An interventional study of Albumin resuscitation and Hydroxyethylstarch resuscitation in Anesthesia Morbidity, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-01-28.
Sponsored by Cairo University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this study we try to review the possible effects when using modern hydroxyethylstarch solutions 6 % versus albumin 5% during living donor renal transplantation.
Cairo University is the lead sponsor of 4,965 studies on the registry; 1,474 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Albumin resuscitation Albumin 5%
Other: Albumin resuscitation · Drug: Albumin 5%
Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%
Other: Hydroxyethylstarch resuscitation · Drug: Hydroxyethylstarch 6%
Albumin 5% is used as the intra-operative colloid
Hydroxyethyl starch 6% is used as the intra-operative colloid
Infusion of Albumin 5% intra-operatively
Also known as: Albumin
Infusion of Hydroxyethylstarch 6% intra-operatively
Also known as: Tetraspan
Occurrence of complications
Increased creatinine and/or need for dialysis
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Feb 2019, 15 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.